Cardiovascular Disease and Androgen Axis–Targeted Drugs for Prostate Cancer

Cardiovascular disease is the leading cause of death in men in the United States and in the developed world. Men with prostate cancer have a higher incidence of cardiovascular disease than those without, and among men with prostate cancer, cardiovascular disease is the principal non–cancer-related cause of death.1,2 The relationship of androgen-deprivation therapy (ADT) to fatal cardiovascular events is uncertain because of conflicting evidence; nonetheless, the general consensus is that men with preexisting cardiovascular disease are at increased risk for cardiovascular toxic effects when treated with ADT.3 The phase 3 HERO trial now reported in the Journal shows that relugolix, . . .